Divalproex Sodium Tablet, Delayed Release
Product Images NDC 17856-0797

6 FDA label images from Atlantic Biologicals Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 17856-0797). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex 250 mg Label (17856 0797 01 Label)

Divalproex 250 mg Label (17856 0797 01 Label)
Packaging label for Divalproex Sodium 250 mg delayed-release tablet, oral use. The label indicates unit dose packaging with one tablet per pouch and 100 tablets per case. Manufactured by Sun Pharmaceuticals Industries Ltd. and repackaged by Unit Dose Solutions, Inc. Distributed by Atlantic Biologicals Corp., Miami, FL. Includes storage instructions and a barcode with NDC 17856-0797-01.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
A bar graph labeled Figure 1 compares percentage values between two groups, PBO and DVPX, across two studies named Study 1 (YMRS) and Study 2 (MRS). The DVPX bars show higher percentages than the PBO bars in both studies, with values of 60% vs 26% in Study 1 and 58% vs 29% in Study 2.*
FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
A cumulative distribution plot labeled Figure 2 comparing the percentage reduction in CPS rate against the percentage of patients for Divalproex Sodium (DVPX) versus placebo. The vertical axis shows percentage reduction from -100% to 100%, indicating worsening to improvement, while the horizontal axis shows percentage of patients from 100% to 0%.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with Divalproex Sodium tablets at high and low doses. The y-axis represents the percent reduction in CPS rate from -100% to 100%, and the x-axis shows the percentage of patients from 100% to 0%. The graph includes curves for both high dose (solid line) and low dose (dashed line) groups, with an annotation indicating improvement or worsening in CPS rate.*
FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' showing comparison of migraine rates between Placebo and Divalproex Sodium (DVPX) in two studies. The chart displays higher migraine rates for Placebo groups versus lower rates for DVPX groups in both Study 1 and Study 2.*
FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Spl-divalproex-structure (Spl Divalproex Structure)
Chemical structure of divalproex sodium, showing the molecular arrangement of its components with sodium ion and carbon chain groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.